前列腺癌肿瘤组织中E-cadherin和N-cadherin的表达及意义  

Expressions of E-cadherin and N-cadherin in prostate cancer and their implications

作　　者：刘祎[1] 陈先国[1] 梁朝朝[1] 

机构地区：[1]安徽医科大学第一附属医院泌尿外科,安徽合肥230022

出　　处：《中华男科学杂志》2014年第9期781-786,共6页National Journal of Andrology

基　　金：国家自然科学基金(81370856);卫生部国家临床重点专科建设项目(2012);教育部博士点基金(20113420110003);安徽省自然科学基金(1208085MH138);安徽省科技攻关项目(12010402128)~~

摘　　要：目的：探讨上皮-间质转化（EMT）相关蛋白E-cadherin和N-cadherin在中低危前列腺癌和高危前列腺癌中的表达差异，以及E-cadherin和N-cadherin的表达与患者年龄、血清PSA水平、肿瘤组织Gleason评分的关系。方法：回顾性分析42例前列腺癌患者临床资料，将前列腺癌分为高危组27例和中低危组15例。免疫组化法检测两组E-cadherin和N-cadherin的表达，并比较两组有无差异；同时分析E．cadherin和N-cadherin的表达阳性率与血清PSA值、肿瘤Gleason评分及患者年龄的关系。结果：E-cadherin在中低危组的表达水平高于高危组（6．1±0．51vs4．2±O．37，P〈0．01），并且在中低危组中表达阳性率显著高于高危组（73．3％vs25．9％，P〈0．01），E-cadherin在PSA〈20μg／L的患者中表达阳性率高于PSAI〉20μg／L的患者（66．7％vs29．6％，P〈0．05），在Glea-son评分5-7分的患者中，其表达阳性率明显高于Gleason评分8～10分的患者（60．9％vs21．1％，P〈0．05）。N-cadherin在中低危组的表达水平低于高危组（3．7±0．32US7．5±0．58，P〈0．01），并且在中低危组中的表达阳性率低于高危组中（13．3％／3559．3％，P〈0．05），在Gleason评分5-7分的患者中，其表达阳性率明显低于Gleason评分8～10分的患者（26．1％vs63．2％，P〈0．05），N-cadherin在PSA〈20μg／L和PSA≥20μg／L的患者中表达阳性率没有差异（P〉0．05）。E-cadherin和N-cadherin在年龄≥70岁和〈70岁的患者中表达阳性率均没有明显差异（P〉0．05）。结论：E-cadherin和N-cadherin在高危前列腺癌和中低危前列腺癌表达阳性率及表达水平存在差异，即两者与前列腺癌的侵袭转移有关，并且E-cadherin和N-cadherin的表达可能与前列腺癌Glesaon评分、血清PSA水平有关。Objective： To investigate the differences in the expressions of E-cadherin and N-cadherin between high-risk prostate cancer and low- and medium-risk prostate cancer, and analyze their correlation with the age, serum PSA level, and Gleason score of the patients. Methods： We retrospectively analyzed the clinical data of 42 cases of prostate cancer, which were divided into a low- and medium-risk group （group A, n = 15 ） and a high-risk group （group B, n = 27 ）. We measured the expressions of E-cadherin and N-cadherin by immunohistochemical staining, compared their differences between the two groups, and analyzed their correlation with the age, serum PSA level, and Gleason score of the patients. Results ： Immunohistochemieal staining showed that the expression of E-cadherin was significantly higher in group A than in B （6.1 ± 0.51 vs 4.2 ± 0.37, P 〈 0.01 ）, and so was its positive rate （73.3%vs 25.9%, P 〈0.05）. The positive rate of E-cadherin was also markedly higher in the patients with serum PSA 〈 20 μg/L than in those with serum PSA≥20μg,/L （66.7% vs 29.6%, P〈0.05）, and so was it in the patients with the Gleason score 5 -7 than in those with 8 - 10 （60.9% vs 21.1%, P 〈0.05）. On the contrary, the N-cadherin expression was significantly lower in group A than in B （3.7 ±0.32 vs 7.5±0.58, P 〈0.01 ）, and so was its positive rate （13.3% vs 59.3%, P 〈0.01 ）. The positive rate of N-cad- herin was also remarkably lower in the patients with the Gleason score 5 -7 than in those with 8 - 10 （26.1% vs 63.2%, P 〈0.05）. However, there were no statistically significant differences in the N-eadherin expression between the patients with serum PSA 〈20 μg/L and those with serum PSA≥20μg/L （P 〉0.05）, nor in the expressions of E-cadherin and N-cadherin between the patients aged ≥70 years and those aged 〈 70 years （P 〉 0.05）. Conclusion ： The expressions of E-cadherin and N-cadherin are significantly different between high-risk prostate cancer and

关 键 词：上皮-间质转化 前列腺癌 E-CADHERIN N-CADHERIN 

分 类 号：R737.25[医药卫生—肿瘤]